Somatostatin analog-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration

William C Santangelo, Roger H Unger, L. Orci, M. I. Dueno, J. J. Popma, G. J. Krejs

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

A 41-year-old woman with metastatic glucagonoma and the characteristic disabling rash, necrolytic migratory erythema, was treated with a synthetic somatostatin analog while waiting to undergo curative surgical resection. Plasma glucagon concentration (1,500-3,300 pg/ml, normal <200) remained elevated during analog therapy as the rash cleared. Only with surgical resection (partial pancreatectomy and partial hepatectomy) did glucagon levels return to normal. The therapeutic benefit caused by the analog in this syndrome differs from that in other endocrine tumor syndromes such as pancreatic cholera, carcinoid, or gastrinoma where circulating levels of tumor-produced agents are suppressed in conjunction with control of symptoms.

Original languageEnglish (US)
Pages (from-to)464-469
Number of pages6
JournalPancreas
Volume1
Issue number5
StatePublished - 1986

Fingerprint

Necrolytic Migratory Erythema
Exanthema
Somatostatin
Glucagon
Vipoma
Glucagonoma
Gastrinoma
Pancreatectomy
Carcinoid Tumor
Hepatectomy
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Endocrinology
  • Gastroenterology

Cite this

Somatostatin analog-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration. / Santangelo, William C; Unger, Roger H; Orci, L.; Dueno, M. I.; Popma, J. J.; Krejs, G. J.

In: Pancreas, Vol. 1, No. 5, 1986, p. 464-469.

Research output: Contribution to journalArticle

@article{af0e015984f14ec4afc83657192f9c48,
title = "Somatostatin analog-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration",
abstract = "A 41-year-old woman with metastatic glucagonoma and the characteristic disabling rash, necrolytic migratory erythema, was treated with a synthetic somatostatin analog while waiting to undergo curative surgical resection. Plasma glucagon concentration (1,500-3,300 pg/ml, normal <200) remained elevated during analog therapy as the rash cleared. Only with surgical resection (partial pancreatectomy and partial hepatectomy) did glucagon levels return to normal. The therapeutic benefit caused by the analog in this syndrome differs from that in other endocrine tumor syndromes such as pancreatic cholera, carcinoid, or gastrinoma where circulating levels of tumor-produced agents are suppressed in conjunction with control of symptoms.",
author = "Santangelo, {William C} and Unger, {Roger H} and L. Orci and Dueno, {M. I.} and Popma, {J. J.} and Krejs, {G. J.}",
year = "1986",
language = "English (US)",
volume = "1",
pages = "464--469",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Somatostatin analog-induced remission of necrolytic migratory erythema without changes in plasma glucagon concentration

AU - Santangelo, William C

AU - Unger, Roger H

AU - Orci, L.

AU - Dueno, M. I.

AU - Popma, J. J.

AU - Krejs, G. J.

PY - 1986

Y1 - 1986

N2 - A 41-year-old woman with metastatic glucagonoma and the characteristic disabling rash, necrolytic migratory erythema, was treated with a synthetic somatostatin analog while waiting to undergo curative surgical resection. Plasma glucagon concentration (1,500-3,300 pg/ml, normal <200) remained elevated during analog therapy as the rash cleared. Only with surgical resection (partial pancreatectomy and partial hepatectomy) did glucagon levels return to normal. The therapeutic benefit caused by the analog in this syndrome differs from that in other endocrine tumor syndromes such as pancreatic cholera, carcinoid, or gastrinoma where circulating levels of tumor-produced agents are suppressed in conjunction with control of symptoms.

AB - A 41-year-old woman with metastatic glucagonoma and the characteristic disabling rash, necrolytic migratory erythema, was treated with a synthetic somatostatin analog while waiting to undergo curative surgical resection. Plasma glucagon concentration (1,500-3,300 pg/ml, normal <200) remained elevated during analog therapy as the rash cleared. Only with surgical resection (partial pancreatectomy and partial hepatectomy) did glucagon levels return to normal. The therapeutic benefit caused by the analog in this syndrome differs from that in other endocrine tumor syndromes such as pancreatic cholera, carcinoid, or gastrinoma where circulating levels of tumor-produced agents are suppressed in conjunction with control of symptoms.

UR - http://www.scopus.com/inward/record.url?scp=0022837908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022837908&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 464

EP - 469

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 5

ER -